日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

High-end talent seeks success in China's fast-growing pharmaceutical sector

By LIU ZHIHUA | China Daily | Updated: 2021-08-10 09:54
Share
Share - WeChat
Workers of Anhui Zhifei Longcom Biopharmaceutical Co Ltd check packaged drugs at the company's plant in Hefei, Anhui province, in May. [Photo/Xinhua]

Chinese biotech companies are becoming increasingly attractive to high-end talent, thanks to the rapid growth of China's healthcare enterprises, according to industry insiders.

Joshua Liang, CEO of Clover Pharmaceuticals, said Chinese local pharmaceutical and biotech companies are attracting not only China-born talent, but also more foreign expertise and returning Chinese.

"The COVID-19 pandemic has made it hard for people overseas to come to China because of quarantine and the travel restrictions, but the trend will resume over the next year or two," Liang said.

"I think this really speaks to the growing innovation of Chinese pharmaceutical and biotech companies, and is a really exciting trend," he said.

Clover has been able to attract top talent from around the world to join its COVID-19 vaccine development program, and currently has employees in the United States, Europe, Southeast Asia and Latin America.

In 2016, Clover had no more than 15 people, who were all lab-based scientists. Now it has over 550 staff in over 15 countries, with a rich pipeline that includes a phase-3 COVID-19 vaccine candidate.

Hays plc, a leading global professional recruiting group, said in a recent report that the rapid development of China's healthcare companies has increased demand for professionals with international experience in the areas including marketing, research and development, digitalization and more.

Although the national healthcare industry has been impacted due to the pandemic, it has been given new development opportunities driven by preferential domestic policy trends and the driving force of the capital market, it said.

"China is the first major economy to recover from the pandemic. The Chinese market has also provided a broad development space for the healthcare industry, where the proportion of local companies is more than ever before. This means rich and diverse job opportunities for candidates," says Simon Lance, managing director of Hays Greater China.

"For Hays, especially in healthcare, domestic clients are a markedly increasing proportion of our overall business. We believe that the growth of local companies will create more opportunities for talent and further drive the healthy flow of expertise to stimulate the innovation potential of Chinese companies," Lance said.

With an attractive salary package and management authority, executives of multinational companies are more willing to join local enterprises to expand their career horizons, while candidates for midlevel positions prefer the mature training systems of multinational companies instead, Hays said.

Local enterprises are normally able to offer attractive remuneration and even equity incentives to talent, it said.

Hays also found that local innovative pharmaceutical companies are paying more attention to their business development divisions and treating them as one of their most crucial core competencies.

The main function of a BD division is "license in and license out"-that means helping the company introduce new patents to save time on R&D, and to sell their pipelines to earn revenue.

Hays said that the BD position requires a candidate to possess a multifaceted skill set. An appropriate candidate must have both pharmaceutical knowledge and good business awareness. Therefore, candidates with doctorate degrees in pharmacy-related majors and business backgrounds are prioritized by employers.

Wei Dong, CEO of EdiGene, a Beijing-based private biotech company developing genome editing technologies, said talent-both locally grown, returnees from overseas-has contributed to the growing pharmaceutical industry's innovation capabilities.

Translating scientific findings into innovative therapies requires a comprehensive understanding of drug development processes, including research, preclinical studies, drug product manufacturing, regulations and clinical trial designs, which take many years of experience, Wei said.

It is natural that scientists and business leaders with experience in multinational companies have become instrumental in founding and growing China's pharmaceutical and biotech startups. But such a trend will shift in the future as new scientific and business leaders emerge from the current boom in innovative biotech companies in China, he said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 欧美日韩亚洲国产 | 欧美性xxxxx极品老少 | 婷婷综合缴情亚洲五月伊 | 又大又粗进出白浆直流动态图 | 欧美日韩亚洲高清不卡一区二区三区 | 狠狠色依依成人婷婷九月 | ⅴideo裸体秀hd | 国产在线观看www鲁啊鲁免费 | 国产精品久久久久久52AVAV | 亚洲午夜av | 国产综合久久久久 | 日韩欧美一区二区不卡 | 精品日韩欧美国产一区二区 | 久草在线中文888 | 999久久久久久久久6666 | 亚洲精品人成网在线播放蜜芽 | 91短视频版在线观看免费大全 | 毛片免费观看视频 | 久久精品二区亚洲w码 | 亚洲狠狠婷婷综合久久久久图片 | 香港午夜三级a三级高清观看 | 欧美一级片手机在线观看 | 亚洲精品日韩在线 | 亚洲午夜成激人情在线影院 | 天天做天天爱夜夜爽女人爽宅 | 久久久久久国产精品免费免费狐狸 | 国产亚洲精品日韩香蕉网 | 一区二区三区视频 | 亚洲三区在线观看 | 欧美色视频网 | 久久精品久 | 欧美18av | 日韩av中文 | 91观看 | 欧美伊人久久综合网 | 亚洲午夜精品视频 | 国产在线观看福利 | 日本va视频| 奇米777四色成人影视 | 91华人在线视频 | 久久三区|